A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction
Launched by LOTUS CLINICAL RESEARCH, LLC · Jul 23, 2014
Trial Information
Current as of June 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • 18- 38 years of age Scheduled to undergo two ipsilateral third molar extractions
About Lotus Clinical Research, Llc
Lotus Clinical Research, LLC is a leading clinical research organization dedicated to advancing medical science through innovative trial management and comprehensive research solutions. With a commitment to quality and integrity, Lotus Clinical Research specializes in conducting Phase I-IV clinical trials across diverse therapeutic areas, including oncology, cardiology, and neurology. The organization leverages a team of experienced professionals and state-of-the-art technology to streamline the research process, ensuring regulatory compliance and optimal patient safety. By fostering collaborative partnerships with sponsors and healthcare providers, Lotus Clinical Research aims to facilitate the timely development of new therapies that improve patient outcomes and enhance public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pasadena, California, United States
Salt Lake City, Utah, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials